Carfilzomib produces OS benefit vs. bortezomib in relapsed, refractory disease

UAMS receives $10.5M NIH grant to develop biomarkers through proteomics

The University of Arkansas for Medical Sciences received a $10.5 million NIH grant to develop biomarkers for all human diseases, including cancer, through proteomics.

December 05, 2025

Vol.51 No.44

In Brief

UAMS Cancer Institute director Michael Birrer inducted into American Academy of Sciences and Letters

Michael J. Birrer, director of the Winthrop P. Rockefeller Cancer Institute at the University of Medical Sciences, has been inducted as a member of the American Academy of Sciences and Letters. xxx:moreBirrer was among more than 60 distinguished scholars inducted during a ceremony Nov. 12 at the historic Decatur House in Washi

November 21, 2025

Vol.51 No.43

In Brief

UAMS Winthrop P. Rockefeller Cancer Institute, ARcare partner to boost CRC screenings in rural Arkansas

A new partnership between the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute and ARcare aims to improve colorectal cancer screening rates in seven rural Arkansas counties where late-stage diagnoses and cancer disparities are on the rise.

July 25, 2025

Vol.51 No.29

In Brief

Fenghuang “Frank” Zhan invested in inaugural Bart Barlogie Chair for Myeloma Research

The University of Arkansas for Medical Sciences College of Medicine invested Fenghuang “Frank” Zhan, a tenured professor of medicine and the research director of the UAMS Winthrop P. Rockefeller Cancer Institute’s Myeloma Center, in the Bart Barlogie Chair for Myeloma Research during a March 13 ceremony. xxx:moreZhan is the inaugural holder of the endowed chair.Zhan’s rese

March 21, 2025

Vol.51 No.11

Drugs & Targets

EU, China approve Sarclisa + standard of care for MM

The EU has approved Sarclisa (isatuximab-irfc) in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant, based on data from the IMROZ phase III study.

January 24, 2025

Vol.51 No.03

In Brief

David Chung named director of clinical research at Northwell Health

Northwell Health appointed David J. Chung, a prominent oncologist-investigator, as director of clinical research at the Northwell Health Cancer Institute. In this newly created role, Chung also will serve as system chief of multiple myeloma across Northwell’s cancer centers.

January 17, 2025

Vol.51 No.02

Carfilzomib produces OS benefit vs. bortezomib in relapsed, refractory disease

YOU MAY BE INTERESTED IN

UAMS receives $10.5M NIH grant to develop biomarkers through proteomics

UAMS Cancer Institute director Michael Birrer inducted into American Academy of Sciences and Letters

UAMS Winthrop P. Rockefeller Cancer Institute, ARcare partner to boost CRC screenings in rural Arkansas

Fenghuang “Frank” Zhan invested in inaugural Bart Barlogie Chair for Myeloma Research

EU, China approve Sarclisa + standard of care for MM

David Chung named director of clinical research at Northwell Health

Renew today!

Subscriber content

Never miss an issue!

Login